Viyash Scientific Q1 FY27: PAT up 115%, margin 21.6%

Results announcement: what the company reported

Viyash Scientific Limited announced its financial results for the first quarter of FY27, for the period ended June 30, 2026. The company said it released unaudited standalone and consolidated results for the quarter. Viyash Scientific was formerly known as Sequent Scientific Limited. The quarter stood out for a sharp improvement in profitability versus the same period last year. Revenue growth was also healthy, according to the consolidated numbers shared by the company.

Q1 FY27 headline numbers: revenue, EBITDA and PAT

For Q1 FY27, Viyash Scientific reported consolidated revenues of ₹9,464 million, up 19.5% year-on-year. EBITDA (excluding ESOP costs) rose to ₹2,047 million, a 59.2% increase over Q1 FY26. Profit after tax (PAT) increased to ₹793 million, up 114.9% year-on-year. The company also disclosed that the net debt to EBITDA ratio stood at 0.1x. Separately, one results summary cited net debt (latest quarter) at 0.2x net debt/EBITDA, indicating a small difference across disclosures.

Margin expansion: EBITDA margin improves to 21.6%

EBITDA margin (excluding ESOP costs) improved to 21.6% in Q1 FY27 from 16.2% in Q1 FY26. The company attributed performance to execution across formulations, APIs, and CDMO services segments. The margin improvement, combined with revenue growth, drove the sharp rise in operating profit. With PAT more than doubling year-on-year, the quarter reflects operating leverage and a stronger profit conversion versus the prior-year period. The company’s reporting explicitly notes that EBITDA is calculated excluding ESOP costs.

Consolidated performance table (as disclosed)

*EBITDA excludes ESOP costs.

Additional numbers cited in the coverage

In regional-language summaries, the quarter’s revenue was also referenced as ₹946.36 crore, and PAT as ₹79.29 crore. These figures are consistent with the consolidated numbers when expressed in ₹ million (₹946.36 crore equals about ₹9,463.6 million; ₹79.29 crore equals about ₹792.9 million). Another disclosed metric was basic EPS of ₹1.51 for the quarter ended June 30, 2026. A separate quick-details summary also listed the previous quarter revenue at ₹919.96 crore (about ₹9,199.6 million) and previous quarter PAT at ₹66.38 crore (about ₹663.8 million), along with a previous quarter EBITDA margin of 21.7%. These additional disclosures provide context on sequential performance references, although the core year-on-year comparison in the company’s table is against Q1 FY26.

Capital structure: net debt to EBITDA remains low

The company disclosed a net debt/EBITDA ratio of 0.1x in its Q1 FY27 highlights. In another results snapshot, net debt was noted at 0.2x net debt/EBITDA for the latest quarter. Both figures, as presented, point to low leverage relative to operating earnings. Since the disclosures present slightly different ratios, investors typically rely on the company’s primary results communication and accompanying notes for reconciliation.

Corporate actions mentioned: rights issue and acquisition

The regional-language coverage also noted approvals related to two corporate actions. First, it referenced a rights issue for subsidiary Alivira Animal Health of up to ₹400.02 crore (about ₹4,000.2 million). Second, it referenced an acquisition of BioForlife Italia for €16.976 million. The article text does not provide further transaction timelines, funding details, or closing conditions beyond these figures and the stated approvals.

Earnings call on August 12: access details and purpose

Viyash Scientific said it will conduct an earnings call with investors on August 12, 2026 at 3:30 PM IST. Management is expected to discuss the company’s performance and answer participant questions during the call. Participants can dial in using +91 22 6280 1263 or +91 22 7115 8213. The company also referenced early registration through a “Diamond Pass” link on its investor relations portal. Another disclosure stated the call is made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015.

Key dates and reference points

Market impact: what the numbers directly indicate

The reported year-on-year jump in EBITDA and PAT, along with a higher EBITDA margin, indicates stronger profitability in Q1 FY27 versus Q1 FY26. Revenue growth of 19.5% provides the base for that improvement, while the margin move from 16.2% to 21.6% shows better operating performance as reported. The company’s low net debt/EBITDA ratio (0.1x as highlighted) suggests limited balance-sheet leverage relative to earnings. The upcoming earnings call provides a structured forum for management to address questions on the quarter’s drivers, segment execution across formulations, APIs, and CDMO services, and any updates linked to the mentioned rights issue and acquisition.

Analysis: why this quarter matters for tracking performance

Q1 FY27 stands out because profitability grew much faster than revenue on a year-on-year basis, as reflected in the 59.2% rise in EBITDA and 114.9% rise in PAT. The EBITDA margin improvement to 21.6% from 16.2% is a key indicator to monitor because it captures changes in operating efficiency and mix, as reported. The disclosure that EBITDA excludes ESOP costs is important for like-to-like comparisons across periods and peer reporting. Separately, the mention of a rights issue for Alivira Animal Health and the acquisition of BioForlife Italia signals ongoing corporate activity that investors may seek more detail on during management interactions, within the boundaries of formal disclosures.

Conclusion

Viyash Scientific’s Q1 FY27 results showed revenue growth to ₹9,464 million and a sharp rise in profitability, with EBITDA margin improving to 21.6% and PAT reaching ₹793 million. The company is scheduled to discuss these results on an investor earnings call on August 12, 2026 at 3:30 PM IST, with dial-in access shared in its communication. Any further clarity on the quarter’s drivers, leverage metrics, and the referenced subsidiary rights issue and overseas acquisition is expected to come through the company’s formal investor interactions and filings.